期刊文献+

单中心192例变异型心绞痛的临床分析 被引量:4

The clinical analysis of 192 patients with variant angina in single center
下载PDF
导出
摘要 目的探讨变异型心绞痛的临床特点及发病机制。方法回顾性分析5年内我院住院患者中192例确诊为变异型心绞痛患者(未行激发试验)的临床资料。结果变异型心绞痛临床上少见,好发于男性,占85.9%,合并危险因素包括吸烟、高血压、饮酒,有过敏史16.7%。心绞痛的好发时间为夜间及凌晨。35例(18.2%)心绞痛发作时合并心律失常,其中室性心动过速11例(5.7%)、心室颤动6例(3.1%)、窦性心动过缓7例(3.6%)、三度房室传导阻滞6例(3.1%);56.9%患者存在冠状动脉固定狭窄,17例(8.9%)合并冠状动脉肌桥。结论变异型心绞痛是冠状动脉痉挛导致的心肌缺血,常合并恶性心律失常,可导致急性心肌梗死甚至猝死。对于狭窄程度严重者应行支架置入术。 Objective To assess the clinical manifestation and mechanism of variant angina. Method The clinical data of 192 patients with variant angina were analyzed retrospectively. Results The disease is uncommon in clinic. It affected men (85. 9%) more frequently than women, the common risk factors included smoking,hypertension and alcohol drinking,and 16.7 % patient had allergy history. Chest pain usually occurred at midnight and in early morning, and responded well to sublingual nitroglycerin. Thirty-five(18.2 %)patients suffered from serious arrhythmia including ventricular tachycardia (11 patients, 5.7 % ), ventricular fibrillation (6 patients, 3.1%), sinus bradycardia(7 patients,3.6%)and m-degree AV block(6 patients, 3. 1%)during chest pain. Significant fixed coronary obstruction occurred in 56.9% patients,and 17(8.9%) patients accompanied with coronary myocardial bridge. Nitrates, calcium antagonists and placement of stents were extremely effective in preventing variant angina. Conclusions Variant angina is caused by coronary spasm and usually accompanied with serious arrhythmia. It can cause myocardial infarction and sudden cardiac death without treatment promptly. Placement of stents in the coronary arteries with severe fixed obstruction is helpful.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2009年第7期502-504,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
基金 教育部博士点专项基金(20070023047) 北京市自然科学基金(7082081)
关键词 冠状动脉疾病 心绞痛 变异型 危险因素 高血压 心律失常 支架 coronary disease angina pectoris, variant risk factors hypertension arrhythmia stents
  • 相关文献

参考文献7

  • 1Sinkiewicz W,Sobanski P,Bartuzi Z.Allergic myocardial infarction.Cardiol J,2008,15:220-225.
  • 2Bertrand ME,LaBlanche JM,Tilmant PY,et al.Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography.Circulation,1982,65:1229-1306.
  • 3Munakata K,Sato N,Sasaki Y,et al.Two cases of variant form angina pectoris associated with myocardial bridge-a possible relationship among coronary vasospasm,atherosclerosis and myocardial bridge.Jpn Circ J,1992,56:1248-1252.
  • 4Tani S,Nagao K,Anazawa T,et al.Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker ; a pilot study.J Cardiovasc Pharmacol,2008,52:28-34.
  • 5Lee J,Cheong SS,Kim J.Association of endothelin-1 gene polymorphisms with variant angina in Korean patients.Clin Chem Lab Med,2008,46:1575-1580.
  • 6Li J J,Zhang YP,Yang P,et al.Increased peripheral circulating inflammatory cells and plasma inflammatory markers in patients with variant angina.Coron Artery Dis,2008,19:293-297.
  • 7Yasue H,Takizawa A,Nagao M,et al.Long-term prognosis for patients with variant angina and influential factors.Criculation,1988,78:1-9.

同被引文献30

  • 1Sato M, Tani E, Fujikawa H, et al. Involvement of Rho-kinase- mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res, 2000,87 (3) : 195-200.
  • 2Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol,2011,7(5) :657-671.
  • 3Otsuka T, Ibuki C, Suzuki T, et al. Administration of the Rho- kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron Artery Dis, 2008,19(2 ): 105-110.
  • 4Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol, 2011,301(2) :287-296.
  • 5Otsuka T, Ibuki C, Suzuki T,ct al. Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. Circ J, 2006,70(4) :402-408.
  • 6Inokuchi K, Ito A, Fukumoto Y, et al. The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit. J Cardiovasc Pharmacol, 2004,44 (3) : 275-277.
  • 7Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy [J]. Can J Physiol Pharmacol ,2008,86 ( 8 ) :485 - 498.
  • 8Moore C, Tymvios C, Emerson M. Functional regulation of vas- cular and platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase [ J ]. Thromb Haemost, 2010, 104(2) :342 -9.
  • 9Kaneda H,Taguchi J,Kuwada Y,et al.Coronary arteryspasm and the polymorphisms of the endothelial nitricoxide synthase gene[J].Circ J,2006,70(4):409-413.
  • 10陈纪林,寇文镕,高润霖,等.变异型心绞痛23例的临床发病特点[J].中国循环杂志,1986,1(2):86.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部